Specifically, α-Klotho may help mitigate NAFLD-driven insulin resistance, thereby reducing the risk of T2DM, alleviating CKD burden, and ultimately lowering CVD risk. The gene discussed is KL; the disease is metabolic dysfunction-associated steatotic liver disease.